COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...

Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral ...

Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...